志愿者女性队列中的骨质疏松治疗缺口
基于FRISBEE队列3560名60至85岁志愿者女性的纵向数据,评估首次主要脆性骨折后1年治疗缺口。386例首次验证脆性骨折中未治疗率85.0%,主要骨质疏松性骨折为82.8%,其他主要骨折为91.0%(p=0.04)。骨质疏松诊断和年龄是仅有的与治疗启动显著相关的临床危险因素。
要点
- 首次主要脆性骨折后1年未治疗率高达85.0%,主要骨质疏松性骨折为82.8%。
- 脊柱骨折未治疗率70.5%、髋部72.5%,低于肩部91.6%和腕部94.1%(p<0.0001)。
- 骨质疏松诊断(p=0.01)和年龄(p=0.03)与治疗启动显著相关。
核心结论
- 首次主要脆性骨折后1年治疗缺口高达85.0%,需加强尤其是医疗专业人员对治疗风险获益平衡的教育。
研究设计与样本
- 基于FRISBEE队列3560名60至85岁志愿者女性的纵向数据,评估首次主要脆性骨折后1年治疗缺口。
主要发现
- 386例首次验证脆性骨折中,285例为主要骨质疏松性骨折,101例为其他主要骨折。
- 未治疗率85.0%,主要骨质疏松性骨折82.8%,其他主要骨折91.0%(p=0.04)。
- 脊柱骨折未治疗率70.5%,髋部72.5%,肩部91.6%,腕部94.1%(p<0.0001)。
- T值<-2.5 SD定义的骨质疏松患者治疗缺口74.6%,依据髋、肩或脊柱骨折定义的骨质疏松患者为76.5%。
- 60-70岁未治疗率87.9%,70-80岁88.2%,80岁以上77.8%(p=0.03);80岁及以下88.1% vs 80岁以上77.8%(p=0.009)。
关键数值与推荐
- 骨质疏松诊断(p=0.01)和年龄(p=0.03)是仅有的与治疗启动显著相关的临床危险因素。
临床怎么用
- 对脆性骨折后女性应主动评估并启动骨质疏松治疗,尤其关注肩部和腕部骨折及80岁以下患者。
局限性
- 研究对象为志愿者女性,可能限制结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Despite the availability of efficient drugs to prevent osteoporotic fractures, only a minority of women receives osteoporosis therapy after a fracture. The high treatment gap in our cohort consisted of unselected volunteer patients highlights the urgent need of additional education, especially for the medical profession, regarding the risk-benefit balance of treatment. INTRODUCTION: Despite the availability of efficient drugs to prevent osteoporotic fractures, only a minority of women receives osteoporosis therapy after a fracture, with a treatment gap around 80%. This can have dramatic consequences for patients and the healthcare systems. METHODS: In this study based on longitudinal data from the FRISBEE (Fracture RIsk Brussels Epidemiological Enquiry) cohort of 3560 volunteer women aged 60 to 85 years, we evaluated the 1-year treatment gap after a first major incident fragility fracture. RESULTS: There were 386 first validated fragility fractures, 285 major osteoporotic fractures (MOF) and 101 "other major" fractures. The rate of untreated patients was 85.0% (82.8% for MOF versus 91.0 % for "other major" fracture sites) (p = 0.04), with a lower rate for spine (70.5%) and hip (72.5%) versus shoulder (91.6%) and wrist (94.1%) (p < 0.0001). More specifically, the treatment gap for patients with osteoporosis, defined by a T-score < - 2.5 SD was 74.6% versus 76.5% for patients with osteoporosis defined by the presence of hip, shoulder, or spine fractures, independently of DXA results. When considering age groups, the rate of untreated women was 87.9% for women 60-70 years old, 88.2% between 70 and 80 years and 77.8% above 80 years (p = 0.03), with a greater difference between women who were younger or older than 80 years at inclusion: 88.1% versus 77.8% (p = 0.009). A diagnosis of osteoporosis (p = 0.01) and age (p = 0.03) were the only clinical risk factors (CRFs) significantly associated with treatment initiation. CONCLUSIONS: This study highlights the urgent need of additional education, especially for the medical profession, regarding the risk-benefit balance of treatment.
引用
- Iconaru L, Smeys C, Baleanu F, et al. Osteoporosis treatment gap in a prospective cohort of volunteer women. Osteoporos Int. 2020. PMID: 32128600. doi:10.1007/s00198-020-05339-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。